A 10-year follow-up of bone mineral density in HIV-infected youths receiving tenofovir disoproxil fumarate

V Giacomet, K Maruca, A Ambrosi, GV Zuccotti, S Mora

Research output: Contribution to journalArticlepeer-review

Abstract

BACKGROUND: The use of tenofovir disoproxil fumarate (TDF) has simplified the antiretroviral regimen for HIV-infected patients and improved their compliance with treatment, but it has been associated with decreased bone mineral density (BMD) in adult patients, and data in pediatric patients are debated. The aim of the current study was to assess the long-term effect of TDF on BMD in young patients. METHODS: BMD was measured at the lumbar spine and in the whole skeleton in 26 HIV-infected youths (13 female and 13 male, aged 5 to 17 years at baseline). BMD was measured yearly for 10 years as part of standard care. BMD changes were compared with those calculated from 202 healthy subjects aged 3 to 24 years. FINDINGS: All patients had good control of the infection during the 10-year study. BMD measurements changed significantly (P
Original languageEnglish
Pages (from-to)365-370
Number of pages6
JournalInternational Journal of Antimicrobial Agents
Volume50
Issue number3
DOIs
Publication statusPublished - 2017

Fingerprint

Dive into the research topics of 'A 10-year follow-up of bone mineral density in HIV-infected youths receiving tenofovir disoproxil fumarate'. Together they form a unique fingerprint.

Cite this